Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Show more

Location: 620 Memorial Drive, Cambridge, MA, 02139, United States | Industry: Biotechnology | Sector: Healthcare


Market Cap

9.491K

52 Wk Range

$0.00 - $0.02

Previous Close

$0.00

Open

$0.00

Volume

2,953

Day Range

$0.00 - $0.00

Enterprise Value

16.7M

Cash

17.26M

Avg Qtr Burn

-18.43M

Insider Ownership

0.14%

Institutional Own.

0.00%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.